-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-U.S. FDA Accepts Supplemental Biologics License Application For Pfizer’S Pneumococcal Conjugate Vaccine

Reuters · 01/06/2023 06:51
BRIEF-U.S. FDA Accepts Supplemental Biologics License Application For Pfizer’S Pneumococcal Conjugate Vaccine

- Pfizer Inc PFE.N:

  • U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR PFIZER’S 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND CHILDREN

  • PFIZER INC - PDUFA GOAL DATE FOR A DECISION BY FDA ON 20VPNC VACCINE APPLICATION IS ANTICIPATED IN APRIL 2023

Source text for Eikon: ID:

Further company coverage: PFE.N


((Reuters.Briefs@thomsonreuters.com;))